Rocket Lab's Neutron Debut Pushed to 2027 Over Tank Manufacturing Flaw

A composite manufacturing defect in the upper dome of the first-stage fuel tank has cost Rocket Lab a full year on its calendar. The company confirmed that the maiden flight of its Neutron launch vehicle will now slip to 2027, abandoning the fourth-quarter 2026 target it had previously held out to investors. The revised schedule was disclosed in an 8-K filing with the U.S. Securities and Exchange Commission on Wednesday, and Reuters reported that the news had already dragged the shares lower in after-hours trading before the regular session opened.

The market's verdict was swift. Rocket Lab stock shed 7.5% during Wednesday's session and closed at EUR 53.10. By the following day the selling had gathered pace, with the equity down 9.7% at EUR 47.95 — a two-day retreat that leaves the shares 64% below their 52-week high. For a company whose smaller Electron rocket already flies commercial missions on a regular basis, the setback matters because Neutron is the vehicle designed to carry substantially heavier payloads and unlock the more lucrative segments of the launch market. Every quarter of delay pushes that revenue further out and keeps capital burning in the meantime.

A Development Program Meets Industrial Reality

Building orbital transport systems ranks among the toughest engineering challenges in high technology, and schedule slippage is hardly unusual when new launch vehicles move from design to production. Rocket Lab attributed the revised timeline to ongoing development work and adjustments in its manufacturing processes, with the tank dome flaw singled out as the specific culprit. Management has not suggested the problem is insurmountable — only that fixing it takes time.

Analysts, however, are recalibrating. On October 9, TD Cowen's Gautam Khanna trimmed his price target on the stock to $90 from $120 while keeping a Buy rating, a cut published as part of his preview of the company's upcoming third-quarter results. The move captures the tension running through the Street: confidence in Rocket Lab's long-term market opportunity remains intact, but the willingness to underwrite rich valuations without near-term proof points is wearing thin.

Not everyone is retreating. Barclays initiated coverage on October 8 with an Overweight rating and an $85 target, while Goldman Sachs maintains a neutral stance and a $75 target, down from $80 previously. The spread of opinions — from $75 to $90 — reflects genuine disagreement about how much patience the Neutron timeline deserves.

Insider Selling Adds to the Caution

Sentiment has not been helped by activity at the top of the company. On October 1, Chief Financial Officer Adam Spice offloaded company shares under a 10b5-1 trading plan. Regulatory filings showed sales across three separate tranches, including blocks of 39,669 and 85,288 common shares. Such transactions are routine by design, executed under pre-arranged schedules that remove discretion from the seller. In a market already on edge, though, they reinforce the wariness building among investors.

What lies ahead is a test of endurance rather than a question of survival. Rocket Lab must demonstrate that the tank issue can be resolved quickly enough to make the 2027 target credible, because the gap between ambition and execution is precisely what the market is now pricing. For shareholders who rode the enthusiasm of recent months, the coming quarters will demand operational evidence — not just stated goals — to justify the valuation.